Charles River Laboratories International, Inc. - CRL STOCK NEWS

Charles River Laboratories (CRL) has signed a multi-program agreement with Pioneering Medicines, enabling access to its AI-driven drug solution, Logica. Designed to expedite drug discovery, Logica combines Valo Health’s Opal Computational Platform and Charles River’s preclinical expertise. The collaboration aims to generate optimized small molecules for unmet medical needs within a 2-year timeframe. This integrated platform is expected to enhance efficiency in drug development, reducing costs tied to success. Flagship Pioneering's initiative, Pioneering Medicines, seeks to leverage innovative platforms to develop transformative treatments.

Charles River Laboratories (NYSE: CRL) has partnered with Purespring Therapeutics to develop a gene therapy platform focused on kidney diseases, affecting about 840 million people globally. This collaboration utilizes Charles River's eXpDNA™ plasmid manufacturing capabilities, bolstering their CDMO services in cell and gene therapy. Purespring aims to innovate treatments targeting podocytes, leveraging a lower-dose, local delivery approach to enhance efficacy and safety. Supported by significant investments, this initiative seeks to accelerate the development of novel therapies, transforming kidney disease treatment and significantly improving patient outcomes.

Charles River Laboratories (NYSE: CRL) has launched its first HCP-ELISA Kit for detecting residual host cell proteins in CHO-based biotherapeutics. This kit boasts an industry-leading sensitivity of 0.1 ng/mL and 90% antibody coverage, utilizing unique chicken IgY antibodies. This method enhances specificity compared to conventional IgG antibodies, which improves impurity control in drug development. The kit supports clients either for self-use or via Charles River’s expert services. This launch is a significant addition to their Biologics Testing portfolio and indicates a continued commitment to pioneering solutions in the biopharmaceutical field.

Charles River Laboratories International, Inc. (NYSE: CRL) will announce its Q4 2022 and full-year 2022 financial results along with guidance for 2023 on February 22, before market opening. A conference call is scheduled for 8:30 a.m. ET on the same day to discuss the results. Investors can access the live webcast through the Investor Relations section of the company's website. Charles River provides critical services and products to pharmaceutical, biotechnology companies, and academic institutions worldwide, aiming to enhance the research and development of new therapies.

Charles River Laboratories (NYSE: CRL) announced the acquisition of SAMDI Tech, Inc. for $50 million, enhancing its drug discovery capabilities through SAMDI's proprietary mass spectrometry technology. This strategic move, marking the culmination of a partnership that began in 2018, aims to improve high-throughput screening (HTS) solutions, accelerating drug discovery timelines and reducing associated costs. The technology offers significant advantages, including minimizing false positives and improving assay conditions. SAMDI Tech will become part of Charles River's Discovery and Safety Assessment segment, expected to augment their comprehensive library of drug discovery solutions.

Charles River Laboratories (NYSE: CRL) has partnered with Rznomics Inc. to utilize its expertise in adenoviral vector production, facilitating the clinical trials of RZ-001, an RNA-based gene therapy targeting hepatocellular carcinoma (HCC). RZ-001, the first ribozyme-based therapy approved by the FDA, aims to treat liver cancer, which accounts for 80% of primary liver cancer cases worldwide. Following its FDA IND approval in October, Rznomics is set to initiate a Phase I/IIa clinical study internationally and in Korea. This collaboration enhances Charles River's established capabilities in gene therapy and manufacturing services, promoting effective clinical development.

Charles River Laboratories (NYSE:CRL) has launched the CliniPrime Fresh Leukopak, a GMP-compliant cellular starting material aimed at accelerating clinical trials and commercialization of advanced therapies. This initial product addresses the critical need for ready access to cGMP-enabled leukocyte materials, reducing client investment and risk. The CliniPrime suite features standardized production processes and complements existing offerings, such as GMPrime products and HemaPrime cellular products. Charles River, with over 40 years in cellular products, continues to support leading developers and researchers in the field.

Charles River Laboratories (NYSE: CRL) announces the launch of its eXpDNA plasmid platform during Phacilitate Advanced Therapies Week from January 17-20, 2023 in Miami, FL. This platform enhances plasmid development and production efficiency, reducing timelines to five weeks for High Quality plasmids and ten weeks for GMP plasmids. It builds on the company's vast experience in biologics testing, supporting multiple advanced therapy clients across various applications. Notable presentations will occur on January 18 and January 19.

Charles River Laboratories (NYSE: CRL) will present at the 41st Annual J.P. Morgan Healthcare Conference on January 10 at 10:30 a.m. PST (1:30 p.m. EST). The presentation will cover strategic focuses, business developments, and recent trends. Investors can access a live webcast through the Investor Relations section of their website, with a replay available for two weeks afterward. Charles River provides vital products and services to pharmaceutical and biotechnology firms, aiding in research and drug development.